Volume 28, Issue 11 (October 2018)
Japanese

Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia. Tai Nobuyuki 1 , Inoue Daisuke 2 1Third Department of Medicine, Teikyo University School of Medicine, Japan. 2Third Department of Medicine, Teikyo University School of Medicine, Japan. pp.1503-1508
Published Date 2018/10/28
DOI https://doi.org/10.20837/42018111503
  • Abstract
  • Look Inside
  • Reference

 Hypercalcemia is a poor prognostic factor and can be a direct cause of death in patients with malignancy. Here we provide a brief overview of pathology, etiology and management of malignancy associated hypercalcemia(MAH). MAH can be divided into two categories:humoral hypercalcemia of malignancy(HHM)caused by a systemic soluble factor secreted by the tumor;and local osteolytic hypercalcemia(LOH)in which tumor cells in situ enhance bone resorption. The standard treatment of MAH is intense hydration along with antiresorptive medications such as calcitonin, bisphosphonate and denosumab.



基本情報

09175857.28.11.jpg
CLINICAL CALCIUM
28巻11号 (2018年10月)
電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有